ORBIFLOXACIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H20F3N3O3
Molecular Weight	395.3756
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C[C@H]1CN(C[C@@H](C)N1)C2=C(F)C(F)=C3C(=O)C(=CN(C4CC4)C3=C2F)C(O)=O

InChI

InChIKey=QIPQASLPWJVQMH-DTORHVGOSA-N

InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+

HIDE SMILES / InChI

Molecular Formula	C19H20F3N3O3
Molecular Weight	395.3756
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Orbifloxacin (brand name Orbax) is a fluoroquinolone antibiotic which is approved for use in dogs and cats, abd marketed by Schering-Plough Animal Health. Orbifloxacin is a synthetic broad-spectrum antibacterial agent from the class of fluoroquinolone carboxylic acid derivatives. Orbifloxacin is the international nonproprietary name for 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid. ORBAX® Oral Suspension is a malt flavored antibiotic suspension containing 30 mg/mL of orbifloxacin and sorbic acid as a preservative. ORBAX® Oral Suspension is indicated for the treatment of urinary tract infections (cystitis) and also for skin and soft tissue infections (wounds and abscesses). Orbifloxacin is bactericidal against a wide range of gram-negative and gram-positive organisms and exerts its antibacterial effect through interference with the bacterial enzyme DNA gyrase which is needed for the maintenance and synthesis of bacterial DNA.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA gyrase 26	Binding Agent 1,064
DNA gyrase 26	Binding Agent 1,064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Urinary tract infections (cystitis) 3	Curative		Approved 8,429	ORBAX
Skin and soft tissue infections 33	Curative		Approved 8,429	ORBAX

PubMed

Show entries

Title	Date	PubMed
Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares.	2001 Jul	11480524
Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs.	2005 Dec	16343288
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].	2007 Jul	17970104
Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats.	2007 Sep	17699040
Implementation of terbium-sensitized luminescence in sequential-injection analysis for automatic analysis of orbifloxacin.	2008 Dec	18958455

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Patents

Sample Use Guides

In Vivo Use Guide

for dogs: oral Suspension is 1.1 to 3.4 mg/lb (2.5 to 7.5 mg/kg) of body weight administered once daily

Route of Administration: Oral

In Vitro Use Guide

The minimum inhibitory concentrations (MICs) of orbifloxacin against 240 field S. intermedius isolates (69 skin and 171 ear isolates) ranged from 0.016 to 8 mg l(-1), with MIC50 and MIC90 equal to 0.5 and 1 mg l(-1), respectively.